U.K Drug-Repurposing Program Expands, Attracts Industry Support
This article was originally published in The Pink Sheet Daily
Britain moves ahead with a drug-repurposing research program that brings together big pharma and academic researchers in novel collaborations.
You may also be interested in...
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
AstraZeneca is giving 15 shelved compounds to U.K.-based academics in a collaboration funded by public money that may produce scientific breakthroughs along with thorny IP issues.
U.K.-based academic research teams will be able to apply to work with the AstraZeneca compounds free of charge and receive grant funding from MRC under the collaboration.